Indeed, both an antibody against FGF2 and an FGFR tyrosine kinase inhibitor (SU5402) have been shown to inhibit SMC proliferation in the setting of vascular injury or atherosclerosis (Lindner & Reidy, 1991; Raj et al, 2006). The gene discussed is FGF2; the disease is atherosclerosis.